03692.HK
Hansoh Pharmaceutical Group Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 32.36
−2.18%Year over year
Reported trailing growth
- Revenue
- +20.5%
- EBITDA
- +30.7%
- EBIT
- +33.8%
- EPS
- +35.8%
- Free cash flow
- +17.0%
- Operating cash flow
- +18.4%
Forward estimates
Based on analyst estimates
- Revenue
- +14.3%
- EBITDA
- -40.4%
- EPS
- -55.0%
Three-year CAGR
- Revenue
- +17.0%
- EBITDA
- +25.3%
- EBIT
- +26.6%
- Net income
- +29.1%
- EPS
- +28.3%
- Free cash flow
- +36.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026